Elevated granzyme M-expressing lymphocytes during cytomegalovirus latency and reactivation after allogeneic stem cell transplantation

Clinical Immunology

Volumn 150, Issue 1, 2014, Pages 1-11

  Bovenschen, Niels ^a   Spijkers, Sanne N M ^a   Wensink, Annette C ^a   Schellens, Ingrid M M ^a   van Domselaar, Robert ^a   van Baarle, Debbie ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cytomegalovirus; Cytotoxic lymphocytes; Granzyme M; GrB; GrM; HCMV; SCT; Stem cell transplantation

Indexed keywords

GRANZYME; GRANZYME M; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PERMEABILIZATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC LYMPHOCYTE; FEMALE; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN CYTOMEGALOVIRUS INFECTION; IN VITRO STUDY; LATENT PERIOD; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER T CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; VIRUS REACTIVATION;

CYTOMEGALOVIRUS; CYTOTOXIC LYMPHOCYTES; GRANZYME B; GRANZYME M; GRB; GRM; HCMV; HUMAN CYTOMEGALOVIRUS; SCT; STEM CELL TRANSPLANTATION;

ADULT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRANZYMES; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; VIRUS ACTIVATION; VIRUS LATENCY; YOUNG ADULT;

EID: 84889634654     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.11.005     Document Type: Article

References (40)

1. Crough T., Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin. Microbiol. Rev. 2009, 22:76-98.
2. Mocarski E.S., Shenk T., Pass R.F. Cytomegaloviruses. Fields Virology 2007, 2701-2772. Lippincott Williams & Wilkins, Philadelphia, PA. P.M. Knipe, D.E. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman, S.E. Straus (Eds.).
3. Hebart H., Einsele H. Clinical aspects of CMV infection after stem cell transplantation. Hum. Immunol. 2004, 65:432-436.
4. Boeckh M., Nichols W.G., Papanicolaou G., Rubin R., Wingard J.R., Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol. Blood Marrow Transplant. 2003, 9:543-558.
5. Sylwester A.W., Mitchell B.L., Edgar J.B., Taormina C., Pelte C., Ruchti F., Sleath P.R., Grabstein K.H., Hosken N.A., Kern F., Nelson J.A., Picker L.J. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 2005, 202:673-685.
6. Elkington R., Walker S., Crough T., Menzies M., Tellam J., Bharadwaj M., Khanna R. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J. Virol. 2003, 77:5226-5240.
7. Khan N., Best D., Bruton R., Nayak L., Rickinson A.B., Moss P.A. T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J. Immunol. 2007, 178:4455-4465.
8. van Domselaar R., Bovenschen N. Cell death-independent functions of granzymes: hit viruses where it hurts. Rev. Med. Virol. 2011, 21:301-314.
9. Bovenschen N., Kummer J.A. Orphan granzymes find a home. Immunol. Rev. 2010, 235:117-127.
10. Chowdhury D., Lieberman J. Death by a thousand cuts: granzyme pathways of programmed cell death. Annu. Rev. Immunol. 2008, 26:389-420.
11. Trapani J.A., Smyth M.J. Functional significance of the perforin/granzyme cell death pathway. Nat. Rev. Immunol. 2002, 2:735-747.
12. Mahrus S., Craik C.S. Selective chemical functional probes of granzymes A and B reveal granzyme B is a major effector of natural killer cell-mediated lysis of target cells. Chem. Biol. 2005, 12:567-577.
13. van Domselaar R., Philippen L.E., Quadir R., Wiertz E.J., Kummer J.A., Bovenschen N. Noncytotoxic inhibition of cytomegalovirus replication through NK cell protease granzyme M-mediated cleavage of viral phosphoprotein 71. J. Immunol. 2010, 185:7605-7613.
14. van Domselaar R., de Poot S.A., Remmerswaal E.B., Lai K.W., ten Berge I.J., Bovenschen N. Granzyme M targets host cell hnRNP K that is essential for human cytomegalovirus replication. Cell Death Differ. 2013, 20:419-429.
15. Gamadia L.E., Rentenaar R.J., Baars P.A., Remmerswaal E.B., Surachno S., Weel J.F., Toebes M., Schumacher T.N., ten Berge I.J., van Lier R.A. Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers. Blood 2001, 98:754-761.
16. van Leeuwen E.M., Remmerswaal E.B., Vossen M.T., Rowshani A.T., Wertheim-van Dillen P.M., van Lier R.A., ten Berge I.J. Emergence of a CD4+ CD28-granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J. Immunol. 2004, 173:1834-1841.
17. Casazza J.P., Betts M.R., Price D.A., Precopio M.L., Ruff L.E., Brenchley J.M., Hill B.J., Roederer M., Douek D.C., Koup R.A. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J. Exp. Med. 2006, 203:2865-2877.
18. Tovar-Salazar A., Patterson-Bartlett J., Jesser R., Weinberg A. Regulatory function of cytomegalovirus-specific CD4+CD27-CD28-T cells. Virology 2010, 398:158-167.
19. Gamadia L.E., Remmerswaal E.B., Weel J.F., Bemelman F., van Lier R.A., Ten Berge I.J. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 2003, 101:2686-2692.
20. Pao L.I., Sumaria N., Kelly J.M., van Dommelen S., Cretney E., Wallace M.E., Anthony D.A., Uldrich A.P., Godfrey D.I., Papadimitriou J.M., Mullbacher A., Degli-Esposti M.A., Smyth M.J. Functional analysis of granzyme M and its role in immunity to infection. J. Immunol. 2005, 175:3235-3243.
21. Pietersma F.L., van Dorp S., Jacobi R., Ran L., Nanlohy N.M., Schuurman R., Minnema M.C., Meijer E., van Baarle D. High level of perforin expression in T cells: an early prognostic marker of the severity of herpesvirus reactivation after allogeneic stem cell transplantation in adults. Clin. Infect. Dis. 2010, 50:717-725.
22. van Baarle D., Hovenkamp E., Callan M.F., Wolthers K.C., Kostense S., Tan L.C., Niesters H.G., Osterhaus A.D., McMichael A.J., van Oers M.H., Miedema F. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood 2001, 98:146-155.
23. Ruys T.A., Nanlohy N.M., van den Berg C.H., Hassink E., Beld M., van de Laar T., Bruisten S., Wit F., Krol A., Prins M., Lange J., van Baarle D. HCV-specific T-cell responses in injecting drug users: evidence for previous exposure to HCV and a role for CD4+ T cells focussing on nonstructural proteins in viral clearance. J. Viral Hepat. 2008, 15:409-420.
24. de Koning P.J., Tesselaar K., Bovenschen N., Colak S., Quadir R., Volman T.J., Kummer J.A. The cytotoxic protease granzyme M is expressed by lymphocytes of both the innate and adaptive immune system. Mol. Immunol. 2010, 47:903-911.
25. van Leeuwen E.M., de Bree G.J., ten Berge I.J., van Lier R.A. Human virus-specific CD8+ T cells: diversity specialists. Immunol. Rev. 2006, 211:225-235.
26. van Leeuwen E.M., ten Berge I.J., van Lier R.A. Induction and maintenance of CD8+ T cells specific for persistent viruses. Adv. Exp. Med. Biol. 2007, 590:121-137.
27. Cheung A.K., Gottlieb D.J., Plachter B., Pepperl-Klindworth S., Avdic S., Cunningham A.L., Abendroth A., Slobedman B. The role of the human cytomegalovirus UL111A gene in down-regulating CD4+ T-cell recognition of latently infected cells: implications for virus elimination during latency. Blood 2009, 114:4128-4137.
28. Mason G.M., Poole E., Sissons J.G., Wills M.R., Sinclair J.H. Human cytomegalovirus latency alters the cellular secretome, inducing cluster of differentiation (CD)4+ T-cell migration and suppression of effector function. Proc. Natl. Acad. Sci. U. S. A. 2012, 10.1073/pnas.1204836109.
29. van Leeuwen E.M., Remmerswaal E.B., Heemskerk M.H., ten Berge I.J., van Lier R.A. Strong selection of virus-specific cytotoxic CD4+ T-cell clones during primary human cytomegalovirus infection. Blood 2006, 108:3121-3127.
30. Tu W., Chen S., Sharp M., Dekker C., Manganello A.M., Tongson E.C., Maecker H.T., Holmes T.H., Wang Z., Kemble G., Adler S., Arvin A., Lewis D.B. Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. J. Immunol. 2004, 172:3260-3267.
31. Bronke C., Palmer N.M., Jansen C.A., Westerlaken G.H., Polstra A.M., Reiss P., Bakker M., Miedema F., Tesselaar K., van Baarle D. Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease. J. Infect. Dis. 2005, 191:873-880.
32. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
33. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 2004, 22:745-763.
34. Moss P., Rickinson A. Cellular immunotherapy for viral infection after HSC transplantation. Nat. Rev. Immunol. 2005, 5:9-20.
35. Einsele H., Roosnek E., Rufer N., Sinzger C., Riegler S., Loffler J., Grigoleit U., Moris A., Rammensee H.G., Kanz L., Kleihauer A., Frank F., Jahn G., Hebart H. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002, 99:3916-3922.
36. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., Riddell S.R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 1995, 333:1038-1044.
37. Leen A.M., Myers G.D., Sili U., Huls M.H., Weiss H., Leung K.S., Carrum G., Krance R.A., Chang C.C., Molldrem J.J., Gee A.P., Brenner M.K., Heslop H.E., Rooney C.M., Bollard C.M. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 2006, 12:1160-1166.
38. Peggs K.S., Thomson K., Samuel E., Dyer G., Armoogum J., Chakraverty R., Pang K., Mackinnon S., Lowdell M.W. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin. Infect. Dis. 2011, 52:49-57.
39. Cobbold M., Khan N., Pourgheysari B., Tauro S., McDonald D., Osman H., Assenmacher M., Billingham L., Steward C., Crawley C., Olavarria E., Goldman J., Chakraverty R., Mahendra P., Craddock C., Moss P.A. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 2005, 202:379-386.
40. Greenberg P.D., Reusser P., Goodrich J.M., Riddell S.R. Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro. Ann. N. Y. Acad. Sci. 1991, 636:184-195.